New York Hospital Queens seeks volunteers for long-term NIH trial comparing type 2 diabetes treatments
New York Hospital Queens (NYHQ) is looking for volunteers to participate in an ongoing clinical research study designed to determine which of four widely-used FDA-approved diabetes medications, when combined with metformin (Glucophage®), is most effective in treating type 2 diabetes. In Queens County, approximately 300,000 individuals have type 2 diabetes, and that number continues to grow every year.
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study aims to expand understanding about how different combinations of medications affect type 2 diabetes over time. Study results are expected to help doctors guide the management of type 2 diabetes in the future.
The GRADE Study is enrolling 5,000 people with type 2 diabetes at nearly 50 medical centers in the U.S., including NYHQ. People with type 2 diabetes may be eligible to join the GRADE Study if they:
- Have had type 2 diabetes for less than 10 years
- Are over 30 years old
- If American Indian, over 20 years old
- Only take metformin (Glucophage®) for their diabetes
- Are willing to take a second diabetes medication
- Are willing to make four office visits per year for the next 4 to 6 years
“If you or someone you know has type 2 diabetes, and continues to have difficulty managing the disease, now may be the right time to consider joining the GRADE study,” said Daniel Lorber, M.D., associate director, Theresa and Eugene M. Lang Center for Research and Education, and director, Endocrinology, NYHQ. “This long-term study will help us understand what combination of diabetes medications works best to enhance an individual’s long-term health.”
Participants in the GRADE study will receive:
- Close follow-up from an expert diabetes care team at no cost
- Diabetes medications and supplies provided at no cost
- Diabetes care visits and lab tests at no cost
- Diabetes education at no cost
Chandan Sinha Roy, who has been a part of the GRADE Study at the Theresa and Eugene M. Lang Center for Research and Education at NYHQ said, “I joined the study nearly one year ago. When I enrolled, I was struggling to manage my diabetes – I was tired and did not want to do anything. Now, I feel a lot better and am back to being active. This study and the expert staff at NYHQ have truly helped to educate me and live well with type 2 diabetes.”
Interested individuals can see if they qualify for enrollment by calling the Theresa and Eugene M. Lang Center for Research and Education at NYHQ, at 718-670-1827. This study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.
GRADE (ClinicalTrials.gov number: NCT01794143) is supported under NIH grant U01DK098246. Additional support in the form of donation of supplies comes from the National Diabetes Education Program, Sanofi-Aventis, Bristol-Myers Squibb, Novo Nordisk, Merck, BD Medical and Roche Diagnostics.
About Type 2 Diabetes
November is American Diabetes Month®. Type 2 diabetes is an epidemic that threatens to become the century’s major public health problem and poses enormous human and economic challenges worldwide. Nearly 26 million Americans are affected by diabetes, and 79 million have pre-diabetes.
About the Theresa and Eugene M. Lang Center for Research and Education at New York Hospital Queens
The Theresa and Eugene M. Lang Center for Research and Education was founded in 2000, to provide a major research presence at New York Hospital Queens. The Center was made possible through a generous gift from philanthropists and friends Theresa and Eugene Lang. The goal of the Center is to promote a new emphasis in clinical research by conducting studies in the community setting. The Center’s activities complement a robust training program for residents and fellows and the higher level of patient care that can be found at NYHQ.